Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
LPL - LPL-ROHINI (NATIONAL REFERENCE LAB)
SECTOR - 18, BLOCK -E ROHINI DELHI 110085
Name
A/c Status
Lab No.
Ref By:
Gender: Age:
Report Status
Reported
Received
Collected
P Final
28/7/2020 12:33:00PM
28/7/2020 2:36:47PM
25 Years Male153672155
UNKNOWN
DUMMY N037
29/7/2020 3:33:39PM
(Real Time PCR)
RESULTS
BCR-ABL gene rearrangement
Negative
Note
1. Sensitivity of the assay is 0.01% when copies of ABL detected is 100,000
2. Limit of detection is 10 copies of BCR-ABL fusion gene transcripts per PCR
3. This is an in-house developed assay designed as per EAC (Europe Against Cancer) protocol
4. This test detects Major (M) gene rearrangements namely- e13a2 & e14a2 and Minor (m) gene
arrangement e1a2. This test does not detect micro gene rearrangement e19a2
5. Test conducted on Whole blood / Bone Marrow
Comments
Chronic Myeloid Leukemia (CML) is the commonest myeloproliferative neoplasm and possibly the
commonest adult leukemia in India. This clonal stem cell disorder is characterized by a proliferation of
myeloid cells at all stages of differentiation and the t(9:22) (q34:q11) leading to formation of BCR-ABL
fusion gene. Cytogenetic and molecular studies are vital for the diagnosis of CML by using detection
procedures for Philadelphia chromosome. The abnormality is present in over 95% patients of CML while
remainder 5% have complex or variant translocations involving additional chromosomes. Major gene
rearrangements are detected in CML while minor gene rearrangement may be detected in ALL.
Uses
· To detect & monitor therapy in CML patients.
· As a prognostic marker in ALL patients. Presence of BCR-ABL gene rearrangement is associated with
poor prognosis.
Dr Anand Chandrasekaran Annan
MD (American Board of Pathology)
PhD (Molecular & Cellular Pathology)
HOD - Oncopathology
Dr Atul Thatai
PhD, Biotechnology
HOD Molecular Diagnostics
NRL - Dr Lal PathLabs Ltd
-------------------------------End of report --------------------------------
PatientReportSCSuperPanel.FLOWCYTO_DYNAMIC_SC (Version: 6)
*153672155*
.
Page 1 of 2
LPL - LPL-ROHINI (NATIONAL REFERENCE LAB)
SECTOR - 18, BLOCK -E ROHINI DELHI 110085
Name
A/c Status
Lab No.
Ref By:
Gender: Age:
Report Status
Reported
Received
Collected
P Final
28/7/2020 12:33:00PM
28/7/2020 2:36:47PM
25 Years Male153672155
UNKNOWN
DUMMY N037
29/7/2020 3:33:39PM
IMPORTANT INSTRUCTIONS
*Test results released pertain to the specimen submitted .*All test results are dependent on the quality of the sample received by the Laboratory .
*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .*Sample
repeats are accepted on request of Referring Physician within 7 days post reporting.*Report delivery may be delayed due to unforeseen
circumstances. Inconvenience is regretted.*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit
request within 72 hours post reporting.*Test results may show interlaboratory variations .*The Courts/Forum at Delhi shall have exclusive
jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*Test results are not valid for medico legal purposes. * Contact
customer care Tel No. +91-11-39885050 for all queries related to test results.
(#) Sample drawn from outside source.
PatientReportSCSuperPanel.FLOWCYTO_DYNAMIC_SC (Version: 6)
*153672155*
.
Page 2 of 2
LPL - LPL-ROHINI (NATIONAL REFERENCE LAB)
SECTOR - 18, BLOCK -E ROHINIDELHI 110085
Name
A/c Status
Lab No.
Ref By:
Gender: Age:
Report Status
Reported
Received
Collected
P Final
28/7/2020 12:00:00AM
28/7/2020 2:36:04PM
32 Years Male153672165
UNKNOWN
DUMMY N038
29/7/2020 3:17:41PM
RESULTS
PML - RARA Type bcr 1
Negative
Note
1. Sensitivity of the assay is 0.01% when copies of ABL detected is 100,000
2. Limit of detection is 10 copies of PML-RARA fusion gene transcripts per PCR
3. This is an in-house developed assay designed as per EAC (Europe Against Cancer) protocol
4. This test detects 3 types of translocations - bcr 1, bcr 2 & bcr 3
5. Test conducted on Whole blood / Bone Marrow
Comments
Acute Promyelocytic Leukemia (APL) is characterized by a unique reciprocal chromosomal translocation
t(15;17) (q22;q11-12) and its underlying fusion gene PML / RARA rearrangement. The fusion is seen between
Promyleocytic (PML) gene on chromosome 15 and RARA gene on chromosome 17. Based on PML
breakpoint location, the PML RARA transcripts subtype bcr 1 & bcr 2 (Long transcript type) and bcr 3 (Short
transcript type) may be formed.
Uses
· For diagnostic identification of PML RARA in cases of Acute Promyelocytic Leukemia
· To assess molecular resistance & predict response to treatments containing ATRA and / or ATO
Dr Anand Chandrasekaran Annan
MD (American Board of Pathology)
PhD (Molecular & Cellular Pathology)
HOD - Oncopathology
Dr Atul Thatai
PhD, Biotechnology
HOD Molecular Diagnostics
NRL - Dr Lal PathLabs Ltd
-------------------------------End of report --------------------------------
PatientReportSCSuperPanel.FLOWCYTO_DYNAMIC_SC (Version: 6)
*153672165*
.
Page 1 of 2
LPL - LPL-ROHINI (NATIONAL REFERENCE LAB)
SECTOR - 18, BLOCK -E ROHINIDELHI 110085
Name
A/c Status
Lab No.
Ref By:
Gender: Age:
Report Status
Reported
Received
Collected
P Final
28/7/2020 12:00:00AM
28/7/2020 2:36:04PM
32 Years Male153672165
UNKNOWN
DUMMY N038
29/7/2020 3:17:41PM
IMPORTANT INSTRUCTIONS
*Test results released pertain to the specimen submitted .*All test results are dependent on the quality of the sample received by the Laboratory .
*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .*Sample
repeats are accepted on request of Referring Physician within 7 days post reporting.*Report delivery may be delayed due to unforeseen
circumstances. Inconvenience is regretted.*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit
request within 72 hours post reporting.*Test results may show interlaboratory variations .*The Courts/Forum at Delhi shall have exclusive
jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*Test results are not valid for medico legal purposes. * Contact
customer care Tel No. +91-11-39885050 for all queries related to test results.
(#) Sample drawn from outside source.
PatientReportSCSuperPanel.FLOWCYTO_DYNAMIC_SC (Version: 6)
*153672165*
.
Page 2 of 2
LPL - LPL-ROHINI (NATIONAL REFERENCE LAB)
SECTOR - 18, BLOCK -E ROHINIDELHI 110085
Name
A/c Status
Lab No.
Ref By:
Gender: Age:
Report Status
Reported
Received
Collected
P Final
28/7/2020 11:48:00AM
28/7/2020 2:34:20PM
25 Years Male153672179
UNKNOWN
DUMMY N045
29/7/2020 3:17:31PM
AML ETO GENE REARRANGEMENT t(8;21)(q22;q22);(RUNX1;RUNX1T1), PCR,
QUALITATIVE
TEST CONDUCTED
(Real Time PCR)
RESULTS
AML ETO t(8;21) Gene Rearrangement
Negative
Note
1. Sensitivity of the assay is 0.01% when copies of ABL detected is 100,000
2. Limit of detection is 10 copies of 8;21 fusion gene transcripts per PCR
3. This is an in-house developed assay designed as per EAC (Europe Against Cancer) protocol
4. Test conducted on Whole blood / Bone Marrow
Comments
Cytogenetic aberrations play a central role in the classification of AML. These aberrations are detected in
50-70% cases of AML by using standard techniques. The AML1(CBFA2, RUNX1)-ETO (MTG8) gene fusion
results from the t(8;21)(q22;q22), which is the commonest chromosomal rearrangement associated with AML,
being detected in approximately 8% of AML cases in children and young adults. Most t(8;21) positive AML’s are
de novo leukemias - vast majority being M2 FAB subtype. This translocation creates chimeric genes encoding
fusion proteins that interfere with the function of CBFα and block the maturation of myeloid cells.
Uses
· For diagnostic identification of AML having morphological, imuunophenotypic or clinical features strongly
suggestive of translocation 8;21
· For prognostic evaluation - Presence of this translocation is associated with a favorable prognosis
Dr Anand Chandrasekaran Annan
MD (American Board of Pathology)
PhD (Molecular & Cellular Pathology)
HOD - Oncopathology
Dr Atul Thatai
PhD, Biotechnology
HOD Molecular Diagnostics
NRL - Dr Lal PathLabs Ltd
-------------------------------End of report --------------------------------
PatientReportSCSuperPanel.FLOWCYTO_DYNAMIC_SC (Version: 6)
*153672179*
.
Page 1 of 2
LPL - LPL-ROHINI (NATIONAL REFERENCE LAB)
SECTOR - 18, BLOCK -E ROHINIDELHI 110085
Name
A/c Status
Lab No.
Ref By:
Gender: Age:
Report Status
Reported
Received
Collected
P Final
28/7/2020 11:48:00AM
28/7/2020 2:34:20PM
25 Years Male153672179
UNKNOWN
DUMMY N045
29/7/2020 3:17:31PM
IMPORTANT INSTRUCTIONS
*Test results released pertain to the specimen submitted .*All test results are dependent on the quality of the sample received by the Laboratory .
*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .*Sample
repeats are accepted on request of Referring Physician within 7 days post reporting.*Report delivery may be delayed due to unforeseen
circumstances. Inconvenience is regretted.*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit
request within 72 hours post reporting.*Test results may show interlaboratory variations .*The Courts/Forum at Delhi shall have exclusive
jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*Test results are not valid for medico legal purposes. * Contact
customer care Tel No. +91-11-39885050 for all queries related to test results.
(#) Sample drawn from outside source.
PatientReportSCSuperPanel.FLOWCYTO_DYNAMIC_SC (Version: 6)
*153672179*
.
Page 2 of 2
LPL - LPL-ROHINI (NATIONAL REFERENCE LAB)
SECTOR - 18, BLOCK -E ROHINIDELHI 110085
Name
A/c Status
Lab No.
Ref By:
Gender: Age:
Report Status
Reported
Received
Collected
P Final
28/7/2020 12:00:00AM
28/7/2020 2:35:56PM
32 Years Male153672167
UNKNOWN
DUMMY N051
29/7/2020 3:18:26PM
NPM1 GENE MUTATIONTEST CONDUCTED
(PCR, Fragment analysis)
RESULTS
NPM1 Gene Mutation
Negative
Note
1. This test detects all types of insertion/deletion NPM1 mutations
2. This is an in-house developed assay
3. Test conducted on Whole blood / Bone Marrow
Comments
Evaluation of NPM1 is recommended in cases of cytogenetically normal AML as detection of these mutations
in the absence of a FLT3 mutation or presence of FLT3 mutation with low allelic ratio (<50%) confers a
favourable prognosis confers a good prognosis and thus NPM1 mutations should always be interpreted with
results of FLT3 mutations. NPM1 mutations are class II mutations which impair hematopoietic differentiation
and subsequent apoptosis. They do not occur in combination with the recurrent cytogenetic abnormalities in
AML and may represent a biologically distinct entity. More than 10 types of NPM mutations have been reported;
types A, B, D together constitute >95% of the mutations.
Uses
· For prognostic evaluation of AML
Dr Anand Chandrasekaran Annan
MD (American Board of Pathology)
PhD (Molecular & Cellular Pathology)
HOD - Oncopathology
Dr Atul Thatai
PhD, Biotechnology
HOD Molecular Diagnostics
NRL - Dr Lal PathLabs Ltd
-------------------------------End of report --------------------------------
PatientReportSCSuperPanel.FLOWCYTO_DYNAMIC_SC (Version: 6)
*153672167*
.
Page 1 of 2
LPL - LPL-ROHINI (NATIONAL REFERENCE LAB)
SECTOR - 18, BLOCK -E ROHINIDELHI 110085
Name
A/c Status
Lab No.
Ref By:
Gender: Age:
Report Status
Reported
Received
Collected
P Final
28/7/2020 12:00:00AM
28/7/2020 2:35:56PM
32 Years Male153672167
UNKNOWN
DUMMY N051
29/7/2020 3:18:26PM
IMPORTANT INSTRUCTIONS
*Test results released pertain to the specimen submitted .*All test results are dependent on the quality of the sample received by the Laboratory .
*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .*Sample
repeats are accepted on request of Referring Physician within 7 days post reporting.*Report delivery may be delayed due to unforeseen
circumstances. Inconvenience is regretted.*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit
request within 72 hours post reporting.*Test results may show interlaboratory variations .*The Courts/Forum at Delhi shall have exclusive
jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*Test results are not valid for medico legal purposes. * Contact
customer care Tel No. +91-11-39885050 for all queries related to test results.
(#) Sample drawn from outside source.
PatientReportSCSuperPanel.FLOWCYTO_DYNAMIC_SC (Version: 6)
*153672167*
.
Page 2 of 2
LPL - LPL-ROHINI (NATIONAL REFERENCE LAB)
SECTOR - 18, BLOCK -E ROHINI DELHI 110085
Name
A/c Status
Lab No.
Ref By:
Gender: Age:
Report Status
Reported
Received
Collected
P Final
28/7/2020 12:20:00PM
28/7/2020 2:35:46PM
26 Years Male153672170
UNKNOWN
DUMMY N052
29/7/2020 2:45:46PM
(PCR, Fragment analysis)
RESULTS
FLT3-ITD
Negative
Note
1. This test detects FLT3-internal tandem duplication (ITD) by fragment analysis on a capillary
electrophoresis system
2. This is an in-house developed assay
3. Test conducted on Whole blood / Bone Marrow
Comments
FLT3 mutations are class I mutations that occur in 30% AML with normal karyotype, AML with t (15; 17),
AML with t(6;9) and in AML with mutated NPM1. The mutations are most commonly internal tandem
duplications. There are also cases of point mutations within the tyrosine kinase domain. The presence of
FLT3 mutations confers a poorer prognosis than in similar cases without FLT3 mutations. Recent studies
indicate that AML with NPM1 mutation and FLT3-ITD low allelic ratio (<50%) may also have a more
favourable prognosis and such patients should not be routinely assigned to allogenic HCT. Also note that
this test is not designed for monitoring residual disease following treatment due to lower sensitivity than
required for MRD assessment.
Uses
· For prognostic evaluation of AML
Dr Anand Chandrasekaran Annan
MD (American Board of Pathology)
PhD (Molecular & Cellular Pathology)
HOD - Oncopathology
Dr Atul Thatai
PhD, Biotechnology
HOD Molecular Diagnostics
NRL - Dr Lal PathLabs Ltd
-------------------------------End of report --------------------------------
PatientReportSCSuperPanel.FLOWCYTO_DYNAMIC_SC (Version: 6)
*153672170*
.
Page 1 of 2
LPL - LPL-ROHINI (NATIONAL REFERENCE LAB)
SECTOR - 18, BLOCK -E ROHINI DELHI 110085
Name
A/c Status
Lab No.
Ref By:
Gender: Age:
Report Status
Reported
Received
Collected
P Final
28/7/2020 12:20:00PM
28/7/2020 2:35:46PM
26 Years Male153672170
UNKNOWN
DUMMY N052
29/7/2020 2:45:46PM
IMPORTANT INSTRUCTIONS
*Test results released pertain to the specimen submitted .*All test results are dependent on the quality of the sample received by the Laboratory .
*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .*Sample
repeats are accepted on request of Referring Physician within 7 days post reporting.*Report delivery may be delayed due to unforeseen
circumstances. Inconvenience is regretted.*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit
request within 72 hours post reporting.*Test results may show interlaboratory variations .*The Courts/Forum at Delhi shall have exclusive
jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*Test results are not valid for medico legal purposes. * Contact
customer care Tel No. +91-11-39885050 for all queries related to test results.
(#) Sample drawn from outside source.
PatientReportSCSuperPanel.FLOWCYTO_DYNAMIC_SC (Version: 6)
*153672170*
.
Page 2 of 2
LPL - LPL-ROHINI (NATIONAL REFERENCE LAB)
SECTOR - 18, BLOCK -E ROHINIDELHI 110085
Name
A/c Status
Lab No.
Ref By:
Gender: Age:
Report Status
Reported
Received
Collected
P Final
28/7/2020 11:45:00AM
28/7/2020 2:34:09PM
26 Years Male153672183
UNKNOWN
DUMMY N062
29/7/2020 2:45:52PM
t(1;19) (q23;p13.3); TCF3- BX1(E2A-PBX1), PCR QUALITATIVETEST CONDUCTED
(Real Time PCR)
RESULTS
t (1;19) (q23 ;p13.3); TCF3-PBX1(E2A- PBX1)
Negative
Comments
Precursor B-cell Acute Lymphoblastic Leukemia (ALL) accounts for 85% Acute leukemias in children
and 20% in adults. Most patients with ALL show an abnormal clone by conventional cytogenetic
studies.The common chromosome translocations in pediatric ALL include t(1;19)(q23;p13.3);
TCF3-PBX1(E2A-PBX1), t(12;21) (p13;q22); ETV6-RUNX1(TEL-AML1) & MLL gene rearrangement. All
these translocations are important to detect as they are important prognostic markers. Detection of
translocation t(1;19) shows improved outcome with intensive chemotherapy.
Uses
· Quantifying disease before treatment and after therapy for patients with ALL
· Assessing residual disease after treatment
Dr Anand Chandrasekaran Annan
MD (American Board of Pathology)
PhD (Molecular & Cellular Pathology)
HOD - Oncopathology
Dr Atul Thatai
PhD, Biotechnology
HOD Molecular Diagnostics
NRL - Dr Lal PathLabs Ltd
-------------------------------End of report --------------------------------
IMPORTANT INSTRUCTIONS
*Test results released pertain to the specimen submitted .*All test results are dependent on the quality of the sample received by the Laboratory .
*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .*Sample
repeats are accepted on request of Referring Physician within 7 days post reporting.*Report delivery may be delayed due to unforeseen
circumstances. Inconvenience is regretted.*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit
request within 72 hours post reporting.*Test results may show interlaboratory variations .*The Courts/Forum at Delhi shall have exclusive
jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*Test results are not valid for medico legal purposes. * Contact
customer care Tel No. +91-11-39885050 for all queries related to test results.
(#) Sample drawn from outside source.
PatientReportSCSuperPanel.FLOWCYTO_DYNAMIC_SC (Version: 6)
*153672183*
.
Page 1 of 1
LPL - LPL-ROHINI (NATIONAL REFERENCE LAB)
SECTOR - 18, BLOCK -E ROHINIDELHI 110085
Name
A/c Status
Lab No.
Ref By:
Gender: Age:
Report Status
Reported
Received
Collected
P Final
28/7/2020 11:46:00AM
28/7/2020 2:34:11PM
29 Years Male153672182
UNKNOWN
DUMMY N063
29/7/2020 2:50:26PM
t(12;21) (p13;q22); ETV6-RUNX1 (TEL-AML1), PCR QUALITATIVETEST CONDUCTED
(Real Time PCR)
RESULTS
t (12; 21) (p13;q22); ETV6-RUNX1(TEL-AML1)
Negative
Comments
Precursor B-cell Acute Lymphoblastic Leukemia (ALL) accounts for 85% Acute leukemias in children and 20%
in adults. Most patients with ALL show an abnormal clone by conventional cytogenetic studies. The common
chromosome translocations in pediatric ALL include t(1;19) (q23 ;p13.3); TCF3-PBX1(E2A-PBX1), t(12; 21)
(p13;q22); ETV6-RUNX1(TEL-AML1) & MLL gene rearrangement. All these translocations are important to
detect as they are important prognostic markers. Detection of translocation t(12;21) which is commonest in
B-ALL is associated with good prognosis in children.
Uses
· Quantifying disease before treatment and after therapy for patients with ALL
· Assessing residual disease after treatment
Dr Anand Chandrasekaran Annan
MD (American Board of Pathology)
PhD (Molecular & Cellular Pathology)
HOD - Oncopathology
Dr Atul Thatai
PhD, Biotechnology
HOD Molecular Diagnostics
NRL - Dr Lal PathLabs Ltd
-------------------------------End of report --------------------------------
IMPORTANT INSTRUCTIONS
*Test results released pertain to the specimen submitted .*All test results are dependent on the quality of the sample received by the Laboratory .
*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .*Sample
repeats are accepted on request of Referring Physician within 7 days post reporting.*Report delivery may be delayed due to unforeseen
circumstances. Inconvenience is regretted.*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit
request within 72 hours post reporting.*Test results may show interlaboratory variations .*The Courts/Forum at Delhi shall have exclusive
jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*Test results are not valid for medico legal purposes. * Contact
customer care Tel No. +91-11-39885050 for all queries related to test results.
(#) Sample drawn from outside source.
PatientReportSCSuperPanel.FLOWCYTO_DYNAMIC_SC (Version: 6)
*153672182*
.
Page 1 of 1
LPL - LPL-ROHINI (NATIONAL REFERENCE LAB)
SECTOR - 18, BLOCK -E ROHINIDELHI 110085
Name
A/c Status
Lab No.
Ref By:
Gender: Age:
Report Status
Reported
Received
Collected
P Final
28/7/2020 11:47:00AM
28/7/2020 2:34:14PM
25 Years Male153672181
UNKNOWN
DUMMY N064
29/7/2020 3:17:23PM
t(4;11) (q21;q23); (MLL-AF4), PCR QUALITATIVETEST CONDUCTED
(Real Time PCR)
RESULTS
t (4;11) (q21;q23); (MLL-AF4)
Negative
Comments
Precursor B-cell Acute Lymphoblastic Leukemia (ALL) accounts for 85% Acute leukemias in children and
20% in adults. Most patients with ALL show an abnormal clone by conventional cytogenetic studies. The
common chromosome translocations in pediatric ALL include t(1;19)(q23;p13.3);TCF3-PBX1(E2A- PBX1),
t(12;21)(p13;q22); ETV6-RUNX1(TEL-AML1) & MLL gene rearrangement. All these translocations are
important to detect as they are important prognostic markers. The t(4;11)(q21;q23) results in the MLL-AF4
fusion gene and is the most frequent MLL translocation in ALL but is rare in AML. Detection of translocation
t(4;11) is seen in 4-6% cases in children and adults. It is generally associated with a poor prognosis.
Uses
· Quantifying disease before treatment and after therapy for patients with ALL
· Assessing residual disease after treatment
Dr Anand Chandrasekaran Annan
MD (American Board of Pathology)
PhD (Molecular & Cellular Pathology)
HOD - Oncopathology
Dr Atul Thatai
PhD, Biotechnology
HOD Molecular Diagnostics
NRL - Dr Lal PathLabs Ltd
-------------------------------End of report --------------------------------
PatientReportSCSuperPanel.FLOWCYTO_DYNAMIC_SC (Version: 6)
*153672181*
.
Page 1 of 2
LPL - LPL-ROHINI (NATIONAL REFERENCE LAB)
SECTOR - 18, BLOCK -E ROHINIDELHI 110085
Name
A/c Status
Lab No.
Ref By:
Gender: Age:
Report Status
Reported
Received
Collected
P Final
28/7/2020 11:47:00AM
28/7/2020 2:34:14PM
25 Years Male153672181
UNKNOWN
DUMMY N064
29/7/2020 3:17:23PM
IMPORTANT INSTRUCTIONS
*Test results released pertain to the specimen submitted .*All test results are dependent on the quality of the sample received by the Laboratory .
*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .*Sample
repeats are accepted on request of Referring Physician within 7 days post reporting.*Report delivery may be delayed due to unforeseen
circumstances. Inconvenience is regretted.*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit
request within 72 hours post reporting.*Test results may show interlaboratory variations .*The Courts/Forum at Delhi shall have exclusive
jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*Test results are not valid for medico legal purposes. * Contact
customer care Tel No. +91-11-39885050 for all queries related to test results.
(#) Sample drawn from outside source.
PatientReportSCSuperPanel.FLOWCYTO_DYNAMIC_SC (Version: 6)
*153672181*
.
Page 2 of 2
LPL - LPL-ROHINI (NATIONAL REFERENCE LAB)
SECTOR - 18, BLOCK -E ROHINIDELHI 110085
Name
A/c Status
Lab No.
Ref By:
Gender: Age:
Report Status
Reported
Received
Collected
P Final
28/7/2020 12:00:00AM
28/7/2020 2:36:39PM
33 Years Male153672162
UNKNOWN
DUMMY N065
29/7/2020 3:19:20PM
t (11;19) (q23;p13.3); (MLL-ENL)TEST CONDUCTED
(Real Time PCR)
RESULTS
t (11;19) (q23;p13.3); (MLL-ENL)
Negative
Comments
Precursor B-cell Acute Lymphoblastic Leukemia (ALL) accounts for 85% Acute leukemias in children and
20% in adults. Most patients with ALL show an abnormal clone by conventional cytogenetic studies. The
common chromosome translocations in pediatric ALL include t(1;19) (q23;p13.3);TCF3-PBX1(E2A-PBX1),
t(12;21) (p13;q22); ETV6-RUNX1 (TEL-AML1) & MLL gene rearrangement. All these translocations are
important to detect as they are important prognostic markers. Translocation t(11;19) (q23;p13.3) generates
MLL-ENL fusion gene which is observed with equal frequency in AML & ALL.
Uses
· Quantifying disease before treatment and after therapy for patients with ALL
· Assessing residual disease after treatment
Dr Anand Chandrasekaran Annan
MD (American Board of Pathology)
PhD (Molecular & Cellular Pathology)
HOD - Oncopathology
Dr Atul Thatai
PhD, Biotechnology
HOD Molecular Diagnostics
NRL - Dr Lal PathLabs Ltd
-------------------------------End of report --------------------------------
IMPORTANT INSTRUCTIONS
*Test results released pertain to the specimen submitted .*All test results are dependent on the quality of the sample received by the Laboratory .
*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .*Sample
repeats are accepted on request of Referring Physician within 7 days post reporting.*Report delivery may be delayed due to unforeseen
circumstances. Inconvenience is regretted.*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit
request within 72 hours post reporting.*Test results may show interlaboratory variations .*The Courts/Forum at Delhi shall have exclusive
jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*Test results are not valid for medico legal purposes. * Contact
customer care Tel No. +91-11-39885050 for all queries related to test results.
(#) Sample drawn from outside source.
PatientReportSCSuperPanel.FLOWCYTO_DYNAMIC_SC (Version: 6)
*153672162*
.
Page 1 of 1
LPL – LPL-ROHINI (NATIONAL REFERENCE LAB) SECTOR - 18, BLOCK -E ROHINI DELHI 110085
*153672142* Note : 1. Metaphases captured by Robotic Microscope 2. Karyogram attached
Name : DUMMY Q005
Lab No. : 153672142 Age : 34 Years Gender: Male
A/c Status : P Ref by : UNKNOWN
Collected: 28-07-2020 12:49:00 Received: 28-07-2020 14:39:04 Reported: 08/08/2020 19:20:05
Report Status: Revised
CHROMOSOME ANALYSIS FOR HEMATOLOGIC MALIGNANCY
Result Summary Normal/Abnormal
Interpretation
Normal Male karyotype. No numerical or structural chromosomal anomalies detected at 450-550 banding resolution. Advised: 1. Microdeletions and cryptic chromosome deletions may not be detected by this method. 2. Results to be clinically correlated.
Specimen Not Specified
Method 24 hr unstimulated cultures with appropriate serum & antibiotics
Banding Method Banding Resolution: 450-550
Stain Name
Cells Analysed
Cells Counted
Karyograms Prepared
GTG
TOTAL
Abbreviations: GTG=G-banding; QFQ=Q-banding;
DAPI=DAPI-staining; CBG=C-banding; AGNOR=Silver-staining; NON=Non-banded The sum of cells analyzed and cells counted equals the total cells examined.
Result* 46,XY
Reason for referral
To rule out any hematological malignancy
*Karyogram attached
.
Page 1 of 2
LPL – LPL-ROHINI (NATIONAL REFERENCE LAB) SECTOR - 18, BLOCK -E ROHINI DELHI 110085
*153672142* Note : 1. Metaphases captured by Robotic Microscope 2. Karyogram attached
Name : DUMMY Q005
Lab No. : 153672142 Age : 34 Years Gender: Male
A/c Status : P Ref by : UNKNOWN
Collected: 28-07-2020 12:49:00 Received: 28-07-2020 14:39:04 Reported: 08/08/2020 19:20:05
Report Status: Revised
Dr Saurabh Kumar Bhattacharya Dr Anand Chandrasekaran Annan
PhD, Cytogenetics MD (American Board of Pathology)
HOD Clinical Cytogenomics NRL - Dr Lal PathLabs Ltd
PhD (Molecular & Cellular Pathology) HOD - Oncopathology
This is a revised report & supersedes all the previously issued reports This is a revised report & supersedes all the previously issued reports
s
IMPORTANT INSTRUCTIONS
*Test results released pertain to the specimen submitted.*All test results are dependent on the quality of the sample received by the Laboratory.
*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring
Physician.*Sample repeats are accepted on request of Referring Physician within 7 days post reporting.*Report delivery may be delayed due to
unforeseen circumstances. Inconvenience is regretted.*Certain tests may require further testing at additional cost for derivation of exact value.
Kindly submit request within 72 hours post reporting.*Test results may show interlaboratory variations.*The Courts/Forum at Delhi shall have
exclusive jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*Test results are not valid for medico legal purposes.
*Contact customer care Tel No. +91-11-39885050 for all queries related to test results.
(#) Sample drawn from outside source.
.
Page 2 of 2